RESUMO
Long synthetic peptides and CpG-containing oligodeoxynucleotides are promising components for cancer vaccines. In this phase I trial, 19 patients received a mean of 8 (range 1-12) monthly vaccines s.c. composed of the long synthetic NY-ESO-179-108 peptide and CpG-B (PF-3512676), emulsified in Montanide ISA-51. In 18/18 evaluable patients, vaccination induced antigen-specific CD8+ and CD4+ T-cell and antibody responses, starting early after initiation of immunotherapy and lasting at least one year. The T-cells responded antigen-specifically, with strong secretion of IFNγ and TNFα, irrespective of patients' HLAs. The most immunogenic regions of the vaccine peptide were NY-ESO-189-102 for CD8+ and NY-ESO-183-99 for CD4+ T-cells. We discovered a novel and highly immunogenic epitope (HLA-DR7/NY-ESO-187-99); 7/7 HLA-DR7+ patients generated strong CD4+ T-cell responses, as detected directly ex vivo with fluorescent multimers. Thus, vaccination with the long synthetic NY-ESO-179-108 peptide combined with the strong immune adjuvant CpG-B induced integrated, robust and functional CD8+ and CD4+ T-cell responses in melanoma patients, supporting the further development of this immunotherapeutic approach.
RESUMO
In near infrared fluorescence-guided surgical oncology, it is challenging to distinguish healthy from cancerous tissue. One promising research avenue consists in the analysis of the exogenous fluorophores' lifetime, which are however in the (sub-)nanosecond range. We have integrated a single-photon pixel array, based on standard CMOS SPADs (single-photon avalanche diodes), in a compact, time-gated measurement system, named FluoCam. In vivo measurements were carried out with indocyanine green (ICG)-modified derivatives targeting the αvß 3 integrin, initially on a genetically engineered mouse model of melanoma injected with ICG conjugated with tetrameric cyclic pentapeptide (ICG-E[c(RGD f K)4]), then on mice carrying tumour xenografts of U87-MG (a human primary glioblastoma cell line) injected with monomeric ICG-c(RGD f K). Measurements on tumor, muscle and tail locations allowed us to demonstrate the feasibility of in vivo lifetime measurements with the FluoCam, to determine the characteristic lifetimes (around 500 ps) and subtle lifetime differences between bound and unbound ICG-modified fluorophores (10% level), as well as to estimate the available photon fluxes under realistic conditions.
RESUMO
Malignant melanoma, the deadliest form of skin cancer, is characterized by a predominant mutation in the BRAF gene. Drugs that target tumours carrying this mutation have recently entered the clinic. Accordingly, patients are routinely screened for mutations in this gene to determine whether they can benefit from this type of treatment. The current gold standard for mutation screening uses real-time polymerase chain reaction and sequencing methods. Here we show that an assay based on microcantilever arrays can detect the mutation nanomechanically without amplification in total RNA samples isolated from melanoma cells. The assay is based on a BRAF-specific oligonucleotide probe. We detected mutant BRAF at a concentration of 500 pM in a 50-fold excess of the wild-type sequence. The method was able to distinguish melanoma cells carrying the mutation from wild-type cells using as little as 20 ng µl(-1) of RNA material, without prior PCR amplification and use of labels.
Assuntos
Melanoma/diagnóstico , Melanoma/genética , Proteínas Proto-Oncogênicas B-raf/genética , RNA/isolamento & purificação , Neoplasias Cutâneas/diagnóstico , Neoplasias Cutâneas/genética , Técnicas Biossensoriais/instrumentação , Técnicas Biossensoriais/métodos , Análise Custo-Benefício , Fragmentação do DNA , Genótipo , Humanos , Melanoma/patologia , Análise em Microsséries/instrumentação , Análise em Microsséries/métodos , Mutação , RNA/genética , RNA Mensageiro/genética , Reação em Cadeia da Polimerase em Tempo Real , Análise de Sequência de RNA , Neoplasias Cutâneas/patologiaRESUMO
Los síndromes poliendocrinos autoinmunes (APS) asocian enfermedades endocrinas autoinmunes con otros desórdenes autoinmunes no endocrinos. El APS tipo II se caracteriza por compromiso primario suprarrenal, tiroideo y/o DM tipo I. Presentamos un paciente masculino de 46 años que fue internado por astenia, adinamia, hiporexia, severa disminución de peso, mareos y vómitos. Antecedente de obesidad y diabetes diagnosticada 3 años antes. Presentaba hipotensión arterial, hiperpigmentación de mucosas y pliegues, anemia, hiponatremia e hipoglucemias frecuentes a pesar de la disminución de la dosis de insulina. Se diagnosticó insuficiencia suprarrenal, concomitantemente con hipotiroidismo y diabetes tipo 1, todas de origen autoinmune, iniciándose reemplazo hormonal. Se encontró una posible asociación del HLA DRB1*-DQB1* en los estudios genéticos. Conclusiones: Nuestro paciente presenta el HLA DQB1*0302 descripto en el APSII, pero el HLA DRB1 *08 encontrado no está descripto en este síndrome ni en ningún otro desorden autoinmune. En pacientes con Diabetes tipo 1 que disminuyan el requerimiento insulínico, habría que descartar insuficiencia suprarrenal, un componente del APS II, como factor etiológico, a pesar de su baja prevalencia.
Autoimmune polyendocrine syndromes (APS) are the association of autoimmune endocrine diseases with other non-endocrine autoimmune disorders. Type II APS is defined by occurrence of Addison´s disease with thyroid autoimmune disease and/or type 1 diabetes mellitus. We present a 46-year-old male patient who was hospitalized because of asthenia, adynamia, hyporexia, severe loss of weight, dizziness and vomiting. Diabetes mellitus had been diagnosed 3 years earlier when he was obese. He presented arterial hypotension, anemia, darkening of the skin and oral mucosa, hyponatremia and frequent hypoglycemia although his insulin dose was decreased. Adrenal insufficiency was diagnosed together with hypothyroidism and type 1 diabetes, all of them of autoimmune origin. Hormonal replacement treatment was initiated. Genetic studies were performed and a new polymorphism was found. Conclusions: HLA DRB1 *08 found in our patient has not been described in APS II or in any other autoimmune disorders. He also has HLA DQB1*0302 described in previous reports related to APS II. In type 1 diabetic patients whose insulin requirement decreases, it would be advisable to rule out adrenal insufficiency, a component of APS II, as an etiologic factor in spite of its low prevalence. In diabetic obese patients (mainly young) who lose weight without a defined cause, type 1 diabetes mellitus should be excluded.
Assuntos
Humanos , Masculino , Pessoa de Meia-Idade , Poliendocrinopatias Autoimunes/complicações , Poliendocrinopatias Autoimunes/diagnóstico , Poliendocrinopatias Autoimunes/imunologia , Estudos de Associação GenéticaRESUMO
La enfermedad tiroidea autoinmune es la patología autoinmune más prevalente y afecta hasta el 5% de la población general. Su desarrollo está dado por la interacción entre susceptibilidad genética y otros factores. Una característica es la temprana producción de anticuerpos antiperoxidasa tiroidea (aTPO) que a menudo predicen el desarrollo clínico de la enfermedad. La susceptibilidad genética para AIT es generada por genes del HLA y por otros candidatos del cromosoma 2q33. Esta región contiene los genes CTLA-4 y CD 28, y sus polimorfismos estarían asociados. Objetivo: Analizar y comparar la distribución de los polimorfismos de simple nucleótido (SNP) de CD28 (IVS3+17 T/C) y CTLA-4 (+49 A/G) en pacientes con aTPO >10 IU/ml (AIT) comparados con un grupo control aTPO ≤ 10 IU/ml sin AIT. Sujetos y métodos: Estudiamos 69 pacientes y 36 sujetos considerados controles. Para determinar aTPO se utilizó IMMULITE 1000 y muestra sérica. Para el estudio de los SNP se extrajo ADN de sangre periférica. La amplificación de los genes se realizó por PCR. Las diferencias entre grupos fueron comparadas usando el test de Chi Cuadrado. Resultados: Observamos diferencia significativa en el genotipo CD28 C/T entre AIT y controles (p=0.026). Analizando los genotipos de los polimorfismos CTLA-4 no observamos diferencia significativa entre AIT y controles. Del análisis de asociación de genotipos CD28 C/T y CTLA-4 A/A o A/G, observamos diferencia significativa comparando AIT vs. controles (p=0,013). Conclusión: Encontramos una posible asociación significativa del genotipo CD28 C/T en individuos con AIT, y estos portadores tendrían un riesgo tres veces mayor de adquirir AIT. La combinación de los genotipos CD28 C/T y CTLA-4 A/A o A/G incrementaría cuatro veces el riesgo de adquirir AIT. Estos resultados permitirían llevar a cabo un diagnóstico precoz, con la adecuada caracterización de una posible enfermedad tiroidea autoinmune en pacientes con AIT.
The autoimmune thyroid disease is the most prevalent autoimmune affection and affects until 5% of the general population; its development is given by the interaction between genetic susceptibility and other factors. One particularity is the early production of thyroid autoantibodies against thyroid peroxidase (aTPO) which often predicts the clinical development of the disease. The genetic susceptibility for the thyroid autoimmunity (AIT) is generated by genes of the HLA and by other genes candidates of the chromosome 2q33. This region contains the genes: CTLA-4 and CD 28. Several polymorphisms of both would be associated according to previous studies. Objective: To analyze and to compare the simple nucleotide polymorphism distribution (SNP) of CD28 (IVS3+17 T/C) and CTLA-4 (+ 49 A/G) in patients with aTPO> 10 IU/ml (AIT) compared to a control group aTPO ≤ 10 IU/ml with no AIT. Subjects and Methods: We have studied 69 patients with AIT and 36 control subjects. Serum aTPO were measured by using chemiluminescence immunoassay (IMMULITE1000, Siemens). Genomic DNA was prepared from peripheral white blood cells. The amplification of the genes was carry out by polymerase chain reaction (PCR). Statistical analyses : the differences between groups were made using the chisquare test. P less than 0.05 was considered statistically significant. Results: There was a significant difference of genotype CD 28 C/T in patients with AIT compared with controls (p=0.026). The genotypes of CTLA-4 was analyzed and there was no significant difference between AIT and controls. Analysis of genotypes association CD 28 C/T and CTLA-4 A/A or A/G, revealed significant difference comparing AIT versus controls (p= 0.013). Conclusions: We found a possible association of genotype CD 28 C/T in individuals with AIT, since carriers of genotype C/T would have a risk three times higher to acquire AIT. The combination of genotypes CD 28 C/T and CTLA-4 A/A or A/G would increase the risk of acquiring AIT four times. These results could be useful in order to make a premature diagnosis, with adequate characterization of a possible autoimmune thyroid disease in patients with AIT.
RESUMO
El APS es la asociación de enfermedades endocrinas autoinmunes, con otros desórdenes autoinmunes no endocrinos, denominados componentes mayores y menores. Este síndrome se clasificó en 4 tipos. Las alteraciones de la respuesta inmune provocan fallas regulatorias de la misma; y polimorfismos de HLA, entre otros, sumado a factores adquiridos o permanentes, representan gatillos disparadores de la autoinmunidad. Nuestro objetivo fue buscar la asociación de HLA-DRB1*-DQB1* en individuos pertenecientes a dos familias, con diagnóstico en uno o más de ellos de APS, o con enfermedades autoinmunes aisladas. Determinar los anticuerpos séricos: a21-OH, aGAD y aTPO y observar la asociación con el haplotipo HLA. Estudiamos padres e hijos de dos familias, dos integrantes padecían APS tipo 2 y 3; y otros con enfermedades autoinmunes. Buscamos HLA-DRB1*-DQB1* y cuantificamos a21-OH, aTPO y aGAD. Los pacientes con APS 2 y 3 presentaron el HLA-DRB1*0301-DQB1*0201. De los individuos estudiados, 5/9 tenían este haplotipo HLA y al menos un autoanticuerpo positivo. Hallamos el factor genético en 2/3 de los integrantes con enfermedades autoinmunes correspondientes a componentes mayores. La relación observada, entre APS y HLA-DRB1*0301-DQB1*0201, aumenta la posibilidad de identificar personas en riesgo de contraer afecciones autoinmunes en grupos familiares, en los cuales algún integrante padece APS.
The APS is the association of autoimmune endocrine diseases, with other non-endocrine autoimmune disorders, named mayor and minor components. This syndrome was classified in 4 types. The alterations of the immune response cause regulatory faults; and HLA polymorphisms, among others; taken in conjunction with acquired or permanent factors, these represent triggers of autoimmunity. Our objective was to find out the association of HLA-DRB1*-DQB1* in individuals belonging to two families, with diagnosis in at least one of them APS, or with isolated autoimmune diseases. To determine serum antibodies: a21-OH, aGAD and aTPO and to observe the association with HLA haplotype. We have studied parents and offspring of two families, two members who suffered APS type 2 and 3, and others with autoimmune diseases. We have looked for HLA-DRB1*-DQB1* and quantified a21-OH, aTPO and aGAD. Patients with APS 2 and 3 showed HLA-DRB1*0301-DQB1*0201. Among the population we have studied, 5/9 had this HLA haplotype and at least one positive auto antibody. We have found the genetic factor in 2/3 of the members with autoimmune diseases corresponding to greater components. The observed relation between APS and HLA-DRB1*0301-DQB1*0201, increases the possibility of identifying people at risk of catching autoimmune affections in familiar groups in which at least one member suffers APS.
RESUMO
AIM: The clinical relevance of sentinel lymph node (SLN) analysis was evaluated prospectively and compared with other known risk factors of relapse in early stage melanoma. METHODS: Surgery was guided by lymphoscintigraphy, blue dye and gamma probe detection. SLN were analysed by haematoxylin eosin (HE) histochemistry and multimarker immunohistochemistry (IHC). Disease free survival (DFS) was evaluated with Kaplan-Meier plots according to different parameters and Cox analyses of variance. RESULTS: From 210 patients a total of 381 SLN were excised. Lymphoscintigraphy identified all excised SLN with only 2 false positive lymphatic lakes. Fifty patients (24%) had tumour positive SLN. With a mean follow-up of 31.3 months, 29 tumour recurrences were observed, 19 (38%) in 50 SLN positive and 10 (6%) in 160 SLN negative patients. Strong predictive factors for early relapse (p < 0.0005) were SLN positivity and a high Breslow index. CONCLUSION: SLN tumour positivity is an independent factor of high risk for early relapse with a higher power of discrimination than the Breslow index.
Assuntos
Melanoma/patologia , Biópsia de Linfonodo Sentinela , Adolescente , Adulto , Idoso , Feminino , Humanos , Masculino , Melanoma/mortalidade , Pessoa de Meia-Idade , Metástase Neoplásica , Recidiva , Fatores de Risco , Análise de SobrevidaRESUMO
BACKGROUND: To be effective and selective, immunotherapy ideally targets specifically tumor cells and spares normal tissues. Identification of tumor specific antigens is a prerequisite to establish an effective immunotherapy. Still very little is known about the expression of tumor-related antigens in pancreatic neoplasms. Cancer Testis antigens (CT) are antigens shared by a variety of malignant tumors, but not by normal tissues with the exception of germ cells in testis. Restricted expression in neoplastic tissues and inherent immunogenic features make CT antigens ideal for use in immunotherapy. We analyzed the expression of a selected panel of nine CT antigens that have been proven to elicit an efficient immunogenic response in other malignancies. In addition we analyzed the expression of HERV-K-MEL, an immunogenic antigen of viral origin. METHODS: Pancreatic adenocarcinoma tumor samples (n=130) were obtained intraoperatively, control tissues (n=23) were collected from cadaveric donor and from patients with chronic pancreatitis. Tumor-associated antigen expression of MAGE-A1, MAGE-A3, MAGE-A4, MAGE-A10, LAGE-1, NY-ESO-1, SCP-1, SSX-2, SSX-4 and HERV-K-MEL was assessed by PCR. Sequencing of PCR products were performed to assess the expression of SSX-4 in neoplastic and normal pancreatic tissues. RESULTS: Three of 10 tested antigens were expressed in over 10% of malignant pancreatic tissue samples. SSX-4 was found positive in 30% of cases, SCP-1 in 19% and HERV-K-MEL in 23% of cases. No expression of CT antigens was found in non-malignant pancreatic tissue with the exception of SSX-4 and and SSX-2. CONCLUSIONS: Fifty two percentage of the analyzed tissues expressed at least one CT antigen. The concomitant expression of SSX-4 in both malignant and non-malignant pancreatic tissue is a new finding which may raise concerns for immunotherapy. However, HERV-K-MEL is expressed with a relatively high prevalence and may be a candidate for specific immunotherapy in a large subgroup of pancreatic cancer patients. This study advocates the analysis of patients with regard to their immunogenic profile before the onset of antigen-specific immunotherapy.
Assuntos
Adenocarcinoma/terapia , Antígenos de Neoplasias/imunologia , Imunoterapia , Neoplasias Pancreáticas/terapia , Adenocarcinoma/imunologia , Azacitidina/administração & dosagem , Sequência de Bases , Primers do DNA , Humanos , Neoplasias Pancreáticas/imunologiaRESUMO
Membrane-bound Fas ligand (FasL, Apo-1L, CD95L) induces rapid apoptosis of Fas (CD95)-sensitive cells on interaction with Fas, and is an important effector molecule of cytolytic T lymphocytes (CTLs). Melanomas are immunogenic and induce the production of specific CTLs, but are usually able to escape immune destruction. We investigated Fas expression and function in 53 cutaneous melanocytic lesions and 13 melanoma cell lines grown in vitro. Immunohistochemical analysis of Fas expression in cutaneous melanocytic lesions showed moderate to high levels of Fas in common benign melanocytic naevi, but low to undetectable levels in atypical naevi, primary (superficial spreading melanoma, nodular melanoma) and cutaneous melanoma metastases. Fluorescence-activated cell sorting (FACS) analysis of Fas expression in melanoma cell lines revealed undetectable or low levels of cell surface Fas expression in five of the 13 melanoma cell lines. Analysis of Fas signalling by quantification of cell death following exposure to recombinant FasL showed that a reduction in Fas expression results in resistance to FasL-mediated cell death. Furthermore, two of the 13 melanoma cell lines were found to be resistant to FasL-mediated cell death despite conserved Fas expression. Thus seven of the 13 melanoma cell lines were found to have impaired Fas signalling. Taken together, our results indicate that downregulation of Fas expression and resistance to Fas-mediated apoptosis are frequent in melanoma.
Assuntos
Apoptose/genética , Regulação Neoplásica da Expressão Gênica , Peptídeos e Proteínas de Sinalização Intracelular , Melanoma/metabolismo , Proteínas de Neoplasias/biossíntese , Neoplasias Cutâneas/metabolismo , Receptor fas/biossíntese , Apoptose/efeitos dos fármacos , Proteína Reguladora de Apoptosis Semelhante a CASP8 e FADD , Proteínas de Transporte/biossíntese , Proteínas de Transporte/genética , Regulação para Baixo , Proteína Ligante Fas , Humanos , Melanócitos/metabolismo , Melanoma/genética , Melanoma/imunologia , Melanoma/patologia , Melanoma/secundário , Glicoproteínas de Membrana/farmacologia , Proteínas de Neoplasias/genética , Proteínas de Neoplasias/fisiologia , Nevo Pigmentado/genética , Nevo Pigmentado/imunologia , Nevo Pigmentado/metabolismo , Nevo Pigmentado/patologia , RNA Mensageiro/biossíntese , RNA Neoplásico/biossíntese , Proteínas Recombinantes/farmacologia , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Neoplasias Cutâneas/genética , Neoplasias Cutâneas/imunologia , Neoplasias Cutâneas/patologia , Células Tumorais Cultivadas/metabolismo , Receptor fas/genética , Receptor fas/fisiologiaRESUMO
The disease caused by Actinomyces spp. is often of difficult diagnosis. Actinomyces spp. are anaerobic or microaerophilic non-spore-forming gram-positive rods that may reach, occasionally, the normal female genital tract. IUD and pessaries facilitate the access of the microorganisms to the pelvis. We report an unusual case of ovarian infection by Actinomyces sp. in a 41 year-old female without IUD, admitted at the Institute in November 1998, with persistent fever. She had had an early menopause 3 years before, and had received hormonal replacement therapy. Usual and unusual infections were discarded by microbiological and serologic studies. Abdominal ultrasonography showed a slight left pyelocalycial dilatation and a simple cyst in the left ovary; heart ultrasonography was normal. Gynecological examination showed an enlarged uterus, similar to an 8 week pregnancy, painless, and fixed anexial masses. The transvaginal ultrasonography showed uterine myomas, one of them of 42 mm in the isthmus region, large ovaries, cystic, with acoustic shadows, and the left one with a septum. The preoperative diagnosis was infected bilateral cystic teratoma. The procedure was an exploratory laparotomy, followed by a bilateral salpingo-oophorectomy. The specimen studies showed an endometrioma with calcium deposits in the wall of the right ovary, and an abscess in the left ovary, also with calcification of the wall. The sample from the left abscess developed Actinomyces sp. After surgery, and treatment with penicillin, the fever disappeared. It is important to remark that the ovarian infection by Actinomyces sp. can also occur in patients without an IUD or a pessary; it might cause anexial images that can be interpreted as a tumour, inducing to erroneous diagnosis and treatment.
Assuntos
Abscesso/diagnóstico , Actinomicose/diagnóstico , Doenças Ovarianas/diagnóstico , Abscesso/cirurgia , Actinomicose/cirurgia , Adulto , Diagnóstico Diferencial , Feminino , Humanos , Dispositivos Intrauterinos , Doenças Ovarianas/cirurgia , Neoplasias Ovarianas/diagnóstico , Teratoma/diagnósticoRESUMO
The peptide derived from the melanoma-associated protein Melan-A (Melan-A(26-35)/HLA-A2) is an attractive candidate for tumor immunotherapy but little is known about the intracellular processing of this antigen. Here we show that Melan-A is a single-pass membrane protein with an NH(2) terminus exposed to the lumen of the exocytic compartment. In transfected melanoma cells, Melan-A accumulates in the Golgi region. Inversion of the membrane topology leads to the retention of Melan-A in the endoplasmic reticulum. Most strikingly, melanoma cells expressing this form of Melan-A are more effectively recognized by specific CTL than those expressing either Melan-A in its native membrane orientation or Melan-A artificially localized in the cytosol. Our data are compatible with the notion that proteins retained in the endoplasmic reticulum are more efficiently degraded and produce more antigenic peptides.
Assuntos
Epitopos , Antígeno HLA-A2/química , Proteínas de Neoplasias/biossíntese , Proteínas de Neoplasias/química , Sequência de Aminoácidos , Antígenos de Neoplasias , Linhagem Celular , Membrana Celular/metabolismo , Cisteína Endopeptidases/farmacologia , Citosol/metabolismo , Relação Dose-Resposta a Droga , Retículo Endoplasmático/metabolismo , Exocitose , Glicosídeo Hidrolases/farmacologia , Complexo de Golgi/metabolismo , Antígeno HLA-A2/biossíntese , Humanos , Cinética , Antígeno MART-1 , Microscopia de Fluorescência , Modelos Biológicos , Dados de Sequência Molecular , Complexos Multienzimáticos/farmacologia , Proteínas de Neoplasias/metabolismo , Peptídeos/química , Plasmídeos/metabolismo , Testes de Precipitina , Complexo de Endopeptidases do Proteassoma , Ligação Proteica , Estrutura Terciária de Proteína , Linfócitos T Citotóxicos/metabolismo , Fatores de Tempo , TransfecçãoRESUMO
MAGE-encoded antigens, which are expressed by tumors of many histological types but not in normal tissues, are suitable candidates for vaccine-based immunotherapy of cancers. Thus far, however, T-cell responses to MAGE antigens have been detected only occasionally in cancer patients. In contrast, by using HLA/peptide fluorescent tetramers, we have observed recently that CD8(+) T cells specific for peptide MAGE-A10(254-262) can be detected frequently in peptide-stimulated peripheral blood mononuclear cells from HLA-A2-expressing melanoma patients and healthy donors. On the basis of these results, antitumoral vaccination trials using peptide MAGE-A10(254-262) have been implemented recently. In the present study, we have characterized MAGE-A10(254-262)-specific CD8(+) T cells in polyclonal cultures and at the clonal level. The results indicate that the repertoire of MAGE-A10(254-262)-specific CD8(+) T cells is diverse both in terms of clonal composition, efficiency of peptide recognition, and tumor-specific lytic activity. Importantly, only CD8(+) T cells able to recognize the antigenic peptide with high efficiency are able to lyse MAGE-A10-expressing tumor cells. Under defined experimental conditions, the tetramer staining intensity exhibited by MAGE-A10(254-262)-specific CD8(+) T cells correlates with efficiency of peptide recognition so that "high" and "low" avidity cells can be separated by FACS. Altogether, the data reported here provide evidence for functional diversity of MAGE-A10(254-262)-specific T cells and will be instrumental for the monitoring of peptide MAGE-A10(254-262)-based clinical trials.
Assuntos
Afinidade de Anticorpos/imunologia , Melanoma/imunologia , Proteínas de Neoplasias/imunologia , Linfócitos T Citotóxicos/imunologia , Anticorpos Monoclonais/imunologia , Anticorpos Antineoplásicos/imunologia , Antígenos de Neoplasias/imunologia , Epitopos de Linfócito T/imunologia , Citometria de Fluxo , Antígeno HLA-A2/imunologia , Humanos , Fragmentos de Peptídeos/imunologia , Células Tumorais CultivadasRESUMO
Activation of CD8(+) cytolytic T lymphocytes (CTLs) by antigen is triggered by the interaction of clonotypic alphabeta T cell receptors (TCRs) with antigenic peptides bound to MHC class I molecules (pMHC complexes). Fluorescent multimeric pMHC complexes have been shown to specifically stain antigen-specific CTLs by directly binding the TCR. In tumor-infiltrating lymphocytes from a melanoma patient we found a high frequency of tyrosinase(368-376) peptide-specific cells as detected by IFN-gamma ELISPOT, without detectable staining with the corresponding A2/peptide multimers. Surprisingly, these T cells were able to lyse tyrosinase(368-376) peptide-pulsed target cells as efficiently as other specific T cells that were stained by multimers. Analysis of the staining patterns under different conditions of incubation time and temperature revealed that these results were explained by major differences in TCR-multimeric ligand interaction kinetics among the clones. Whereas no direct quantitative correlation between antigenic peptide concentration required for CTL effector functions and equilibrium multimer binding was observed interclonally, the latter was profoundly affected by the kinetics of TCR-ligand interaction. More importantly, our data indicate that similar levels of T cell activation can be achieved by independent CD8(+) T cell clonotypes displaying different TCR/pMHC complex dissociation rates.
Assuntos
Antígeno HLA-A2/metabolismo , Interferon gama/metabolismo , Receptores de Antígenos de Linfócitos T/metabolismo , Linfócitos T Citotóxicos/imunologia , Células Clonais , Ensaio de Imunoadsorção Enzimática , Antígeno HLA-A2/química , Meia-Vida , Humanos , Técnicas In Vitro , Cinética , Ligantes , Linfócitos do Interstício Tumoral/imunologia , Substâncias Macromoleculares , Melanoma/imunologia , Receptores de Antígenos de Linfócitos T/químicaRESUMO
The development of soluble tetrameric MHC/peptide complexes has opened the possibility to directly identify and monitor antigen-specific CD8+ T cells in different clinical situations. This represents a technological breakthrough for the field of cell-mediated immunity. For example, the direct identification and enumeration of tumor-specific CD8+ T cells at the tumor site and in blood has recently provided compelling evidence that strong anti-tumoral responses naturally occur in some cancer patients. Moreover, the use of tetramers plays an essential role in the design of vaccination protocols aimed at inducing a strong and protective CD8+ T cell-mediated anti-tumoral response in cancer patients. The monitoring of antigen-specific T cell responses elicited by various peptide-based vaccines tested in phase I clinical trials clearly indicates that tumor-specific CD8+ T cells can be activated effectively at least in some cancer patients. Thus, multiparameter monitoring of antigen-specific T cell responses that combines ex vivo tetramer staining with various phenotyping and functional assays provides a novel approach to assess the functional potential of tumor-specific T lymphocytes and may also facilitate the optimization of vaccination protocols.
Assuntos
Linfócitos T CD8-Positivos/imunologia , Cadeias Pesadas de Miosina/farmacologia , Neoplasias/imunologia , Animais , Linfócitos T CD8-Positivos/efeitos dos fármacos , Humanos , Imunoterapia , Neoplasias/terapia , Peptídeos/farmacologiaRESUMO
Adenocarcinomas (AC) account for more than 90% of the prostatic malignant neoplasias; a neuroendocrine differentiation (NE) component is to be considered in cases of atypical evolution for its diagnostic and therapeutic relevance. The (NE) originates by proliferation of the NE cells of the acinar epithelium and may develop into two different histologic patterns, a "Carcinoid" type and a "Small Cell" type. We report a patient with a prostatic AC diagnosed 5 years before his death with worsening of the disease together with a return of the prostatic specific antigen (PSA) to normal values and the presence of hepatic metastases of a tumor (NE) of the small cell type. The autopsy confirmed the presence of a prostatic tumor with areas of (AC) type and (NE) small cell type and multiple hepatic metastases (NE).
Assuntos
Adenocarcinoma/patologia , Carcinoma de Células Pequenas/patologia , Sistemas Neurossecretores/patologia , Antígeno Prostático Específico/sangue , Neoplasias da Próstata/patologia , Idoso , Transformação Celular Neoplásica , Evolução Fatal , Humanos , Masculino , Tumores Neuroendócrinos/patologiaRESUMO
We have shown previously that HLA-A*0201 melanoma patients can frequently develop a CTL response to the cancer testis antigen NY-ESO-1. In the present study, we have analyzed in detail the relative antigenicity and in vitro immunogenicity of natural and modified NY-ESO-1 peptide sequences. The results of this analysis revealed that, although suboptimal for binding to the HLA-A*0201 molecule, peptide NY-ESO-1 157-165 is, among natural sequences, very efficiently recognized by specific CTL clones derived from three melanoma patients. In contrast, peptides NY-ESO-1 157-167 and NY-ESO-1 155-163, which bind very strongly to HLA-A*0201, are recognized less efficiently. In agreement with previous data, substitution of peptide NY-ESO-1 157-165 COOH-terminal C with various other amino acids resulted in a significantly increased binding to HLA-A*0201 molecules as well as in an increased CTL recognition, although variable at the clonal level. Among natural peptides, NY-ESO-1 157-165 and NY-ESO-1 157-167 exhibited good in vitro immunogenicity, whereas peptide NY-ESO-1 155-163 was poorly immunogenic. The fine specificity of interaction between peptide NY-ESO-1 C165A, HLA-A*0201, and T-cell receptor was analyzed at the molecular level using a series of variant peptides containing single alanine substitutions. The findings reported here have significant implications for the formulation of NY-ESO-1-based vaccines as well as for the monitoring of either natural or vaccine-induced NY-ESO-1-specific CTL responses in cancer patients.
Assuntos
Antígenos de Neoplasias , Antígenos/metabolismo , Linfócitos T CD8-Positivos/imunologia , Linfócitos T CD8-Positivos/metabolismo , Proteínas de Membrana , Proteínas/metabolismo , Ligação Competitiva , Separação Celular , Relação Dose-Resposta a Droga , Citometria de Fluxo , Antígeno HLA-A2/metabolismo , Humanos , Interferon gama/metabolismo , Melanoma/metabolismo , Microscopia de Fluorescência , Peptídeos/química , Peptídeos/metabolismo , Ligação Proteica , Células Tumorais CultivadasRESUMO
Peptide-based vaccines are currently being tested for their ability to induce or augment tumor antigen (Ag)-specific CD8+ T-cell responses in cancer patients. Here we report that the frequency of circulating CD8+ T cells directed against the Melan-A/MART-1 Ag increased >20-fold in an HLA-A2 melanoma patient immunized repeatedly with the corresponding antigenic peptide, as assessed by staining with HLA-A2/peptide tetramers. Multiparameter flow cytometric analysis demonstrated that the increase in total Melan-A-specific cell number was accompanied by a marked increase in the proportion of the cells that expressed an activated/memory surface phenotype. As assessed by ELISPOT assays and intracellular staining, the absolute number of Melan-A-specific cells able to secrete IFN-gamma increased >50-fold upon vaccination. When tested directly after cell sorting on the basis of tetramer staining, Melan-A-specific cells were weakly cytolytic but became highly active after in vitro restimulation. Altogether, these results indicate that large numbers of functionally active tumor Ag-specific CD8+ T cells can be obtained and maintained at high levels after in vivo activation by repeated peptide-based vaccination.
Assuntos
Linfócitos T CD8-Positivos/metabolismo , Vacinas Anticâncer/química , Melanoma/imunologia , Anticorpos Monoclonais/metabolismo , Antígenos de Neoplasias , Divisão Celular , Citometria de Fluxo , Granzimas , Humanos , Interferon gama/metabolismo , Linfócitos/metabolismo , Antígeno MART-1 , Melanoma/metabolismo , Proteínas de Neoplasias/química , Proteínas de Neoplasias/metabolismo , Neoplasias/imunologia , Neoplasias/metabolismo , Peptídeos/metabolismo , Fenótipo , Serina Endopeptidases/metabolismo , Fatores de TempoRESUMO
In this study we assessed the expression of the Melan-A/MART-1 antigen by immunohistochemistry using monoclonal antibody A103 in 73 primary cutaneous melanomas and its correlation with tumor staging and patient survival. Melan-A/MART-1 was expressed in 90% of primary tumors, with loss of expression increasing with Breslow thickness. Kaplan-Meier analysis demonstrated a significantly reduced disease-free interval and overall survival rate for patients not expressing this antigen. The poor prognosis of such patients was even worse for those presenting with a primary melanoma and a Breslow thickness of > or = 1 mm. Thus, Melan-A/MART-1 is not only a useful and specific additional marker for the diagnosis of primary cutaneous melanoma, but it may also help refine the prognosis of patients with malignant melanoma.
Assuntos
Melanoma/diagnóstico , Melanoma/metabolismo , Proteínas de Neoplasias/biossíntese , Neoplasias Cutâneas/diagnóstico , Neoplasias Cutâneas/metabolismo , Antígenos de Neoplasias , Progressão da Doença , Intervalo Livre de Doença , Feminino , Humanos , Imuno-Histoquímica , Antígeno MART-1 , Masculino , Análise Multivariada , Prognóstico , Fatores de TempoRESUMO
MAGE genes encode tumor-specific shared antigens that are among the most interesting candidates for cancer vaccines. Despite extensive studies, however, CD8+ T-cell responses to MAGE-derived epitopes have been detected only occasionally in cancer patients, even after vaccination. In contrast with these findings, we report here that HLA-A2 melanoma patients respond frequently to the recently identified peptide MAGE-A10(254-262). Indeed, as assessed by staining with fluorescent HLA-A2/peptide MAGE-A10(254-262) tetramers, CD8+ T cells directed against this peptide were readily detectable in a large proportion of HLA-A2+ melanoma patients. These results provide new insight into the immunogenicity of MAGE antigens and underline the potential usefulness of MAGE-A10 peptide-based cancer vaccines.
Assuntos
Melanoma/imunologia , Proteínas de Neoplasias/imunologia , Oligopeptídeos/imunologia , Linfócitos T Citotóxicos/imunologia , Animais , Anticorpos Monoclonais/farmacologia , Antígenos de Neoplasias , Células COS , Citotoxicidade Imunológica/efeitos dos fármacos , DNA Recombinante , Relação Dose-Resposta a Droga , Antígeno HLA-A2/genética , Antígeno HLA-A2/imunologia , Humanos , Proteínas de Neoplasias/química , Proteínas de Neoplasias/genética , Oligopeptídeos/genética , Oligopeptídeos/farmacologia , Plasmídeos/genética , Células Tumorais Cultivadas , Fator de Necrose Tumoral alfa/metabolismoRESUMO
Recent studies have shown that CTL epitopes derived from tumor-associated Ags can be encoded by both primary and nonprimary open reading frames (ORF). In this study we have analyzed the HLA-A2-restricted CD8(+) T cell response to a recently identified CTL epitope derived from an alternative ORF product of gene LAGE-1 (named CAMEL), and the highly homologous gene NY-ESO-1 in melanoma patients. Using MHC/peptide tetramers we detected CAMEL(1-11)-specific CD8(+) T cells in peptide-stimulated PBMC as well as among tumor-infiltrated lymph node cells from several patients. Sorting and expansion of tetramer(+) CD8(+) T cells allowed the isolation of tetramer(bright) and tetramer(dull) populations that specifically recognized the peptide Ag with high and low avidity, respectively. Remarkably, only high avidity CAMEL-specific CTL were able to recognize Ag-expressing tumor cells. A large series of HLA-A2-positive melanoma cell lines was characterized for the expression of LAGE-1 and NY-ESO-1 mRNA and protein and tested for recognition by CAMEL-specific CTL as well as CTL that recognize a peptide (NY-ESO-1(157-165)) encoded by the primary ORF products of the LAGE-1 and NY-ESO-1 genes. This analysis revealed that tumor-associated CD8(+) T cell epitopes are simultaneously and efficiently generated from both primary and nonprimary ORF products of LAGE-1 and NY-ESO-1 genes and, importantly, that this occurs in the majority of melanoma tumors. These findings underscore the in vivo immunological relevance of CTL epitopes derived from nonprimary ORF products and support their use as candidate vaccines for inducing tumor specific cell-mediated immunity against cancer.